Skip to main content

Table 1 Clinical features for patients in the genome screen

From: Genome wide screen identifies microsatellite markers associated with acute adverse effects following radiotherapy in cancer patients

Characteristic

initial genome screen

focused screen

Difference between groups (P)

 

LGG-1

HGG-1

LGG-2

HGG-2

 
 

(n = 90)

(n = 90)

(n = 90)

(n = 90)

 

Age at RT

     

Mean ± SD

59.7 ± 14.6

59.7 ± 11.5

62.5 ± 12.8

59.5 ± 11.1

0.434

Range

26-89

38-83

38-88

21-79

 

Family history of cancer

33 (36.7%)

23 (25.6%)

42 (46.7%)

37 (41.1%)

0.129

Cancer type

     

Breast

42

7

42

7

 

Cervical

15

27

15

27

 

Esophageal

4

15

4

15

 

Head and neck

10

30

9

31

 

Lung

18

10

19

9

 

Prostate

1

1

1

1

 

TNM classification

     

T1

50

13

46

22

 

T2

30

30

27

35

 

T3

8

34

11

26

 

T4

2

13

6

7

 

N0

72

43

72

40

 

N1

12

30

13

27

 

N2

6

10

4

17

 

N3

0

6

1

5

 

N4

0

0

0

1

 

M0

90

78

87

81

 

M1

0

12

3

9

 

Dose of radiotherapy (Gy)*

     

Breast

49.6 ± 1.4

49.9 ± 0.6

0.602

Cervical

50.2 ± 4.3

50.7 ± 3.9

0.704

Esophageal

54.2 ± 11.3

50.7 ± 8.6

0.776

Head and neck

65.0 ± 5.9

65.3 ± 3.9

0.8

Lung

52.1 ± 8.9

51.4 ± 10.8

0.715

Grade of adverse event**

     

0

30

0

25

0

 

1

60

0

65

0

 

2

0

0

0

0

 

3

0

84

0

74

 

4

0

6

0

16

 
  1. * Average dose was obtained only for patients treated with photon therapy. Prostate cancer was treated using brachytherapy or particle therapy.
  2. **Adverse event mainly: dermatitis for breast cancer; diarrhea, bone marrow suppression for cervical cancer; dysphagia, bone marrow suppression for esophageal cancer; dermatitis, mucositis for head and neck cancer; pneumonitis, bone marrow suppression for lung cancer; dysuria for prostate cancer.
  3. Abbreviations: LGG = Low grade group, HGG = High grade group, RT = radiotherapy, TNM = Tumor Node Metastasis.